Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025
Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025 |
| [02-September-2025] |
New customer launches representing 107,000 lives covered reinforce Dario's B2B2C momentum and recurring revenue growth Dario's multi-condition digital health solutions deliver real-time results for prediabetes, diabetes, and hypertension resulting in a 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user 80% of the new accounts signed in 2025 are for multi-condition programs Pipeline of commercial opportunities increases to $67 million NEW YORK, Sept. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the launch of five new contracts with self-insured employers. All five programs went live during the second and third quarters of 2025 and feature Dario's full cardiometabolic suite, highlighting continued demand for integrated, multi-condition solutions.  "We believe that employer contracts continue to be a powerful driver of near-term growth for Dario," said Steven Nelson, Dario's President and Chief Commercial Officer. "Building on previously announced wins and these five recent employer contracts, and supported by our robust $67 million pipeline of opportunities across employers, health plans, and pharmaceutical clients, we remain confident in our ability to reach approximately 40 new client signings by year-end 2025—a 35% increase over 2024 and a meaningful milestone on our path to profitability. Most notably, one of these five contracts is with an employer that is our largest to date, which we believe demonstrates our continued momentum with the largest and most discerning companies looking to deploy value-driven digital health solutions to improve outcomes while reducing costs." Dario's cardiometabolic suite helps improve quality of life for people living with prediabetes, diabetes and hypertension as demonstrated through the following:
About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. Cautionary Note Regarding Forward-Looking Statements This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the launch of five new contracts with self-insured employers will contribute to annual recurring revenues beginning the third quarter of 2025; that the new customer launches reinforce B2B2C momentum and recurring revenue growth; that employer contracts will continue to be a powerful driver of near-term growth; the $67 million pipeline of commercial opportunities; that the Company remains confident in its ability to reach approximately 40 new client signings by year-end 2025; and that the new client signings are a meaningful milestone to its path to profitability. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. DarioHealth Corp. Corporate Contacts: Zoe Harrison DarioHealth Corp. Investor Relations Contact: Michael Lipari Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
SOURCE DarioHealth Corp. | ||
Company Codes: Berlin:LS1P.BE,NASDAQ:DRIO,NASDAQ-CM:DRIO |
View original content:
